Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
BriaCell Therapeutics Corp. Market Cap
Based on ratings from 2 stock analysts, the BriaCell Therapeutics Corp. stock price is expected to increase by 1288.89% in 12 months. This is calculated by using the average 12-month stock price forecast for BriaCell Therapeutics Corp.. The lowest target is $15 and the highest is $15. Please note analyst price targets are not guaranteed and could be missed completely.
BriaCell Therapeutics Corp. has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that BriaCell Therapeutics Corp. will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of BCTX.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Emily Bodnar HC Wainwright & Co. | Buy | $15 | Reiterates | Dec 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $15 | Reiterates | Oct 3, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $15 | Maintains | Sep 19, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $18 | Reiterates | Sep 11, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $18 | Reiterates | Jun 4, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $18 | Reiterates | May 24, 2024 |
| Emily Bodnar HC Wainwright & Co. | Buy | $18 | Reiterates | Dec 28, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $20 | Maintains | Oct 3, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $25 | Reiterates | Jun 28, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $25 | Reiterates | Feb 24, 2023 |
| Emily Bodnar HC Wainwright & Co. | Buy | $25 | Initiates | Feb 14, 2022 |
When did it IPO
2010
Staff Count
16
Country
Canada
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. William V. Williams M.D.
Market Cap
$39.1M
In 2023, BCTX generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that BCTX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 02 Dec 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics' Phase 3 study of Bria-IMT™ in metastatic breast cancer has been recommended for continuation by the Data Safety Monitoring Board, under FDA's Fast Track Designation.
Why It Matters - The DSMB's recommendation to continue BriaCell's Phase 3 study signals confidence in the safety and potential effectiveness of its cancer treatment, positively impacting investor sentiment and stock value.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics Corp. has announced the immediate resignation of board member Marc Lustig. The board expressed gratitude for his contributions to the company.
Why It Matters - Leadership changes can impact investor confidence and company direction. Marc Lustig's resignation may raise concerns about BriaCell's stability and future strategy.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics will showcase positive survival data from its Bria-IMT™ and CPI combination in metastatic breast cancer patients at the 2024 San Antonio Breast Cancer Symposium.
Why It Matters - BriaCell's positive data on its cancer immunotherapy could enhance its market position and attract investors, potentially leading to increased stock value and interest in its clinical developments.
Thu, 21 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics has initiated a Phase 1/2 study for its personalized immunotherapy, Bria-OTS™, in metastatic breast cancer, testing it alone and with BeiGene's tislelizumab®.
Why It Matters - The start of BriaCell's Phase 1/2 study for Bria-OTS™ signals potential advancements in cancer treatment, impacting stock performance and investor sentiment in biotech.
Fri, 08 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics reported strong preclinical data for its personalized immunotherapies, Bria-BRES+™ and Bria-PROS+™, at the SITC 39th Annual Meeting, indicating potential in breast and prostate cancer treatment.
Why It Matters - Strong preclinical data for BriaCell's new cancer immunotherapies may enhance investor confidence, potentially increasing stock value and attracting interest in the biotech sector.
Mon, 04 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - BriaCell Therapeutics will present five posters, including a Spotlight presentation, at the SABCS 2024 from December 10-13 in San Antonio, Texas.
Why It Matters - BriaCell's presentations at a major cancer symposium highlight its progress in immunotherapy, potentially boosting investor confidence in its innovation and future market performance.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
